Article Abstract

Locoregional and oligometastatic recurrence of esophageal cancer—what are the management strategies?

Authors: Monisha Sudarshan

Abstract

Over the past few decades, prognosis of esophageal cancer has improved with the advent of multimodality treatment and refinement of surgical techniques and perioperative care. A 5% 5-year survival across all stages was quoted in the 1960s which has evolved to a 20% all stage 5-year survival today (1). Clearly the reality of esophageal cancer is still grim and there is progress to be made. Within the cohort of patients that are operable, nearly 50% of patients will recur (2).